Physician profile
Eric Antwi-Donkor
NPI 1629053848
$2,005.13
in general payments reported to CMS, 2019-2025
15 companies · $617 in 2025
The $617 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2021: $292 · 2022: $527 · 2023: $82.74 · 2024: $338 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $616 · Consulting Fee: $225 · Food and Beverage: $196 · Education: $0.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $616.06 |
| Consulting Fee | $225.00 |
| Food and Beverage | $196.00 |
| Education | $0.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $616.06 | 2025 | Symplicity G3 |
| Vifor Pharma, INC. | $384.32 | 2021-2023 | Veltassa |
| Amgen INC. | $298.79 | 2021-2023 | Parsabiv |
| Travere Therapeutics, INC. | $225.78 | 2024-2025 | Filspari |
| Aurinia Pharma U.S., INC. | $112.96 | 2022-2023 | Lupkynis |
| Baxter Healthcare | $66.28 | 2019 | |
| Novartis Pharmaceuticals Corporation | $61.11 | 2024 | |
| Ardelyx, INC. | $52.15 | 2024 | Ibsrela |
| Mallinckrodt Enterprises LLC | $51.77 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.41 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $38.74 | 2019-2022 | |
| Glaxosmithkline, LLC. | $19.42 | 2023 | Benlysta |
| Otsuka America Pharmaceutical, INC. | $13.42 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.71 | 2022 | |
| Fresenius USA Marketing, INC. | $12.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Antwi-Donkor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.